Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

Journal of Hepatology

Volumn 59, Issue 4, 2013, Pages 658-666

  Cammà, Calogero ^a   Petta, Salvatore ^a   Cabibbo, Giuseppe ^a   Ruggeri, Matteo ^b   Enea, Marco ^a   Bruno, Raffaele ^c   Capursi, Vincenza ^a   Gasbarrini, Antonio ^b   Alberti, Alfredo ^d   Craxì, Antonio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

^d VENETIAN INSTITUTE OF MOLECULAR MEDICINE   (Italy)

Author keywords

Boceprevir; Cost effectiveness; Telaprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

ADULT; ARTICLE; CAUCASIAN; CLINICAL EVALUATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; GENOTYPE; HEPATITIS C; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RELAPSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

BOC; BOCEPREVIR; CHC; CHRONIC HEPATITIS C; COST-EFFECTIVENESS; DT; DUAL THERAPY; G1; GENOTYPE 1; ICER; INCREMENTAL COST-EFFECTIVENESS RATIO; NON-RESPONSE; NR; PAR; PARTIAL RESPONSE; PEGIFN; PEGYLATED INTERFERON; PI; PROTEASE INHIBITORS; RBV; RELAPSE; RIBAVIRIN; RR; TELAPREVIR; TVR;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; ITALY; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; OLIGOPEPTIDES; PROLINE; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT FAILURE;

EID: 84884411831     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.05.019     Document Type: Article

References (41)

1. J.G. McHutchison, E.J. Lawitz, M.L. Shiffman, A.J. Muir, G.W. Galler, and J. McCone Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection N Engl J Med 361 2009 580 593
2. B.J. Veldt, E.J. Heathcote, H. Wedemeyer, J. Reichen, W.P. Hofmann, and S. Zeuzem Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis Ann Intern Med 147 2007 677 684 (Pubitemid 351664462)
3. J. Bruix, T. Poynard, M. Colombo, E. Schiff, K. Burak, and E.J. Heathcote Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C Gastroenterology 140 2011 1990 1999
4. A.M. Di Bisceglie, M.L. Shiffman, G.T. Everson, K.L. Lindsay, J.E. Everhart, and E.C. Wright Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
5. C. Cammà, D. Di Bona, and F. Schepis Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data Hepatology 39 2004 333 342 (Pubitemid 38222174)
6. S. Bruno, A. Crosignani, and C. Facciotto Sustained viroLogic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study Hepatology 51 2010 2069 2076
7. C. Cammà, M. Giunta, and P. Andreone Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach J Hepatol 34 2001 593 602 (Pubitemid 32328518)
8. A.G. Singal, M.L. Volk, and D. Jensen A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus Clin Gastroenterol Hepatol 8 2010 280 288
9. T. Poynard, M. Colombo, J. Bruix Epic Study Group Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628
10. D.M. Jensen, P. Marcellin, and B. Freilich Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial Ann Intern Med 150 2009 528 540
11. C. Cammà, G. Cabibbo, and F. Bronte Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: a meta-analysis J Hepatol 51 2009 675 681
12. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
13. M. Ghany, D. Nelson, and D. Strader An update on treatment of genotype 1 chronic hepatitis c virus infection: 2011 practice guidelines by the American Association for the Study of Liver Diseases Hepatology 2011 2011 10.1002/hep.24641
14. B.R. Bacon, S.C. Gordon, E. Lawitz HCV RESPOND-2 Investigators Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
15. S. Zeuzem, P. Andreone, S. Pol REALIZE Study Team Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
16. FDA Antiviral Drugs Advisory Committee Meeting. Boceprevir. < http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AntiviralDrugsAdvisoryCommittee/UCM254079.pdf > [accessed August 3, 2011].
17. Victrelis [boceprevir]. European Medicines Agency. < http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/ 002332/human-med-001464.jsp > [accessed August 17, 2011].
18. FDA Antiviral Drugs Advisory Committee Meeting. Telaprevir. < http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/AntiviralDrugsAdvisoryCommittee/UCM252562.pdf >.
19. Incivo [telaprevir]. European Medicines Agency. < http://www.ema. europa.eu/docs/en-GB/document-library/EPAR-product-Information/human/002313/ WC500115529.pdf >.
20. A.C. Cardoso, R. Moucari, and C. Figueiredo-Mendes Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis J Hepatol 52 2010 652 657
21. A.J. Drummond, S.Y. Ho, and M.J. Phillips Relaxed phylogenetics and dating with confidence PLoS Biol 4 2006 e88
22. ISTAT, Tavole di mortalità della popolazione italiana 2010. < http://dati.istat.it/?lang=it >.
23. A.J. Freeman, G.J. Dore, and M.G. Law Estimating progression to cirrhosis in chronic hepatitis C virus infection Hepatology 34 2001 809 816 (Pubitemid 32928008)
24. C. Cammà, V. Di Marco, and G. Cabibbo Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems Aliment Pharmacol Ther 28 2008 62 75 (Pubitemid 351782806)
25. M. Angelico, U. Cillo, S. Fagiuoli Liver Match Investigators Liver match, a prospective observational cohort study on liver transplantation in Italy: study design and current practice of donor-recipient matching Dig Liver Dis 43 2011 155 164
26. M. Guido, S. Fagiuoli, and G. Tessari HistoLogy predicts cirrhotic evolution of post transplant hepatitis C Gut 50 2002 697 700 (Pubitemid 34407500)
27. L. Benvegnù, F. Noventa, and E. Bernardinello Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development Gut 48 2001 110 115 (Pubitemid 32042650)
28. G. D'Amico, G. Garcia-Tsao, and L. Pagliaro Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies J Hepatol 44 2006 217 231 (Pubitemid 41772537)
29. R Development Core Team R: a language and environment for statistical computing 2011 R Foundation for Statistical Computing Vienna, Austria 3-900051-07-0 < http://www.R-project.org/ >
30. U. Siebert, G. Sroczynski, S. Rossol German Hepatitis C Model (GEHMO) Group International Hepatitis Interventional Therapy (IHIT) Group Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C Gut 52 2003 425 432 (Pubitemid 36250066)
31. J.A. Salomon, M.C. Weinstein, and J.K. Hammitt Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population JAMA 290 2003 228 237 (Pubitemid 37430062)
32. F. Sassi Calculating QALYs, comparing QALY and DALY calculations Health Policy Plan 21 2006 402 408 (Pubitemid 44594426)
33. S.D. Sullivan, A. Craxì, and A. Alberti Cost effectiveness of peginterferon alfa-2a plus ribavirin versus interferon alfa-2b plus ribavirin as initial therapy for treatment-naïve chronic hepatitis C Pharmacoeconomics 22 2004 257 265 (Pubitemid 38393394)
34. A. Alberti Impact of a sustained virological response on the long-term outcome of hepatitis C Liver Int 31 2011 18 22
35. L. Munari, and A. Picciotto Recombinant interferon alfa-2b therapy for chronic hepatitis C in Italy: an economic analysis FORUM Trends Exp Clin Med 6 1996 347 353 (Pubitemid 26345655)
36. Conferenza delle Regioni e Provincie Autonome. Tariffa Unica Concenzionale per le prestazioni di assistenza ospedaliera. Regole e tariffe valide per il 2006. Roma, 15 dicembre 2005.
37. Libro Bianco AISF. < www.webaisf.org/media/13891/libro-bianco-aisf- 2011.pdf >; 2011.
38. B. Jonsson Changing health envìronment: the challenge to demonstrate cost-effectiveness of new compounds Pharmacoeconomics 22 2004 5 10 (Pubitemid 40066088)
39. E.H. Elbasha, J. Chhatwal, S.A. Ferrante, A.C. El Khoury, and P.A. Laires Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis C virus genotype 1 infection in Portugal Appl Health Econ Health Policy 11 2013 65 78
40. D. Callahan Health technology assessment implementation: the politics of ethics Med Decis Making 2011 [epub ahead of print]
41. Hezode C, Dorival C, Zoulim F, et al. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French Early Access Program (ANRS CO20-CUPIC). In: 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012), Barcelona, April 18-22, 2012, Abstract 8.